Cigna Corporation

🇺🇸New York Stock Exchange
Back to all articles
Cigna Corporation stock analysis CI overview
Slightly Bullish +25

CVS vs Cigna: Which Healthcare Giant Belongs in Your Retirement Portfolio?

📊 CVS Health trades at an 11.3x trailing adjusted earnings multiple compared to Cigna's 9.4x.

💰 CVS offers a 3.5% dividend yield with $2.66 in annualized dividends, while Cigna yields roughly 2.3%.

⚠️ CVS net income fell 62.55% year-over-year due to a $5.7B goodwill impairment and litigation charges.

📈 Cigna reported strong net income growth of 73.47% in FY2025, reaching $5.957 billion.

🏥 CVS Health Care Benefits segment faces a turnaround as operating income fell 45.28%.

💼 Cigna has beaten adjusted EPS estimates in all four quarters of 2025 with consistent execution.

📉 Cigna's Evernorth pharmacy business saw 17% revenue growth and expanded to 123.6 million customers.

💹 CVS generated $10.639 billion in operating cash flow for FY2025 compared to Cigna's guidance of at least $9.0 billion for the same period.

🔄 Over the past decade, Cigna has returned over 100% to shareholders versus just 1.84% for CVS.

📉 Cigna repurchased approximately $3.6 billion worth of shares in 2025 to shrink its share count.

🛒 CVS same-store prescription volume rose 9.7% while Pharmacy & Consumer Wellness revenue grew 12.4%.

🏃‍♂️ Cigna improved its SG&A ratio significantly from 5.9% to 5.0% year-over-year.

📉 While CVS stock is up 17.32% recently, Cigna stock has declined by 14.51% over the same period.

🎯 For long-term wealth building (10-15 years), Cigna is viewed as a stronger holding due to capital discipline.

⚖️ Retirees prioritizing current income may prefer CVS's higher yield and potential for turnaround upside.

Bullish Signals
  • Cigna (CI) reported strong net income growth of 73.47% year-over-year, reaching $5.957 billion in FY2025.
  • The company demonstrates consistent execution by beating adjusted EPS estimates in all four quarters of 2025.
  • Cigna's Evernorth pharmacy business posted robust revenue growth of 17% in Q4 2025, with pharmacy customers expanding to 123.6 million.
  • Operating discipline is evident as the SG&A ratio improved significantly from 5.9% to 5.0% year-over-year.
  • Cigna has returned capital aggressively to shareholders by repurchasing approximately 11.9 million shares for $3.6 billion in 2025.
  • Over a long-term decade period, Cigna has compounded shareholder returns of 101.36%, far outpacing the historical average.
  • Cigna trades at an attractive valuation with forward P/E around 9.3x based on its strong earnings quality.
Risk Factors
  • CVS Health net income plummeted by 62.55% year-over-year in FY2025, a drop driven by a massive $5.7 billion goodwill impairment and approximately $1.2 billion in legacy litigation charges.
  • The company reduced its 2026 operating cash flow guidance from $10 billion to at least $9.0 billion, signaling potential financial pressure or margin deterioration ahead.
  • Operating income for CVS fell sharply by 45.28% year-over-year despite showing some pharmacy momentum.
  • While Cigna has strong growth, CVS faces a specific challenge that requires proving its Health Care Benefits segment can stabilize before becoming a stronger holding.
  • CVS stock is down significantly relative to peers in the long term over a decade, having returned just 1.84% compared to Cigna's 101.36%, which may indicate structural underperformance.
Full Analysis
This article compares CVS Health (CVS) and Cigna Group (CI) for retirement portfolios, highlighting divergent financial trajectories and investment profiles. The content notes that while CVS trades at approximately 11.3x trailing adjusted earnings with a 3.5% dividend yield generated on $76.07 in shares, it suffered a significant net income decline of 62.55% in FY2025 driven by a $5.7B goodwill impairment and $1.2B in litigation charges. In contrast, Cigna trades at roughly 9.4x trailing earnings with stronger earnings quality, reporting a 73.47% year-over-year net income increase to $5.957B, having beaten adjusted EPS estimates in all four quarters of 2025 by margins ranging from 0.65% to 6.17%. The analysis emphasizes Cigna's consistent execution and capital discipline, citing a pharmacy business (Evernorth) that grew revenue by 17% in Q4 2025 and expanded customers to 123.6 million, alongside an improvement in SG&A ratio from 5.9% to 5.0%. Over the past decade, Cigna has returned over 100% to shareholders, primarily through a $3.6B share repurchase program in 2025 and aggressive dividend growth, whereas CVS has seen long-term total returns of only 1.84% over ten years despite pharmacy segment momentum showing 9.7% same-store volume growth. CVS is positioned as a choice for retirees prioritizing current income and stability, offering a massive $402 billion revenue base and recent price performance gains of 17.32%, though it requires stabilization in its Health Care Benefits segment. Cigna is presented as the superior holding for long-term wealth compounding over a 10-to-15-year horizon due to its lower forward multiple of roughly 9.3x, shrinking share count, and proven consistency even after a recent price performance decline of 14.51%. The piece concludes that Cigna is likely the stronger holding for growth-oriented retirement investors despite CVS's attractive dividend yield.